Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.22.1
SEGMENT INFORMATION (Tables)
3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information
The following table presents information by reportable operating segment for the three months ended March 31, 2022 and 2021 (in thousands):
Consumer Products
Segment
Specialty Pharmaceutical Segment Consolidated Totals
Three months ended March 31, 2022:
Product sales, net $ 4,447  $ —  $ 4,447 
Gross profit $ 1,156  $ —  $ 1,156 
Research and development expense 117  121 
Selling, general and administrative expense 2,519  31  2,550 
Operating loss $ (1,480) $ (35) $ (1,515)
Three months ended March 31, 2021:
Product sales, net $ 4,844  $ —  $ 4,844 
Gross profit $ 2,358  $ —  $ 2,358 
Research and development expense 128  58  186 
Selling, general and administrative expense 5,270  15  5,285 
Operating loss $ (3,040) $ (73) $ (3,113)